Compare CHMI & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHMI | PMVP |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | 14 | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.5M | 76.8M |
| IPO Year | N/A | 2020 |
| Metric | CHMI | PMVP |
|---|---|---|
| Price | $2.38 | $1.06 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | 214.5K | ★ 277.1K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 15.09% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $61.13 | N/A |
| P/E Ratio | $139.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.17 | $0.96 |
| 52 Week High | $3.04 | $1.88 |
| Indicator | CHMI | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 45.43 | 33.12 |
| Support Level | $2.25 | $1.04 |
| Resistance Level | $2.46 | $1.26 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 48.39 | 12.00 |
Cherry Hill Mortgage Investment Corp is a fully integrated, internally managed residential real estate finance company focused on acquiring, investing in and managing residential mortgage assets in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.